- Date: October 20, 2022
Mi-Trial Launches Innovative New Clinical Trials App And Portal To Improve Trial Participation And Outcomes
- 3 min read
Mi-Trial is a clinical trial companion system and app. It has been designed to meet the needs of both trial participants and those managing trials, with important benefits for the integrity of the trial that help all partners. There are two major components: the patient-facing app, and the portal from which the trial scheduling is managed.
The portal and app were developed by experts in trials design and delivery, working closely with experts in software design and usability. This combination of expertise gives Mi-Trial the flexibility and function required to meet the needs of trial participants and trial centre staff, as well as the usability required to make it an integral part of trial delivery. By improving the trials experience and protocol adherence for participants, this reduces visit errors and data wastage, saving time and costs for both trial centres and sponsors.
● Single repository for all trial information
● Scheduling tool to sync with own diary
● Reminders about restrictions and important information
● Access to trial contact details
● Ability to submit feedback to trial organisation
Available as iOS, Android and web-based app
● Enhance adherence to trial protocol
● Reduce protocol deviations, wasted visits and costs associated with this
● Maintain engagement with participant
● Easy to access and manage platform for reviewing participant details and mapped journey
● One-stop scheduler
● User-friendly, flexible interface
● Allows a range of notifications to be sent to participants, reducing workload
● Single platform to manage much of trial experience (visit setup, communication with patients, sharing documents, monitoring participants)
The Mi-Trial team has input from NIHR Clinical Researchers, clinical academics, a trial organisation and a digital health company, to enhance the quality of our solution
The Mi-Trial Portal allows trial sponsors or organisations to dynamically and intelligently configure a range of study structures thanks to a bespoke scheduling algorithm
Hosted on Amazon Web Services, Mi-Trial is a secure platform using 2-Factor Authentication (2FA) and other industry-leading cybersecurity standards
The restriction reminders and notifications in Mi-Trial reduce the number of erroneous or void study visits, improving study protocol adherence
Alex is a Professor of Respiratory Medicine at the University of Manchester, consultant at the Manchester Adult Cystic Fibrosis (CF) Centre, and CF academic lead for the NIHR Manchester Biomedical Research Centre. He is a director of the NIHR Manchester Clinical Research Facility at Wythenshawe Hospital, where he oversees trials activity in a wide range of specialties. He is responsible for initiating and maintaining one of the largest CF trials programs in the country, having led >20 trials of new therapies in CF since 2012 and making Manchester one of the leading sites for CF clinical trials internationally. He has been national or global lead on trials of several ground-breaking therapies, including transformative new CFTR modulator therapies. He has experience at all phases of clinical trials and has also designed and delivered clinical trials in acute COVID19.
Jacky is a Professor of Respiratory Medicine at the University of Manchester and an Honorary Consultant at Manchester University NHS Foundation Trust. She runs a multi-disciplinary research team which focuses on understanding mechanisms underlying pathological cough and a regional clinical service seeing patients with refractory chronic cough. She is also the Director of the NIHR Manchester Clinical Research Facility and Leads the Rapid Translational Incubator Theme of the NIHR Manchester Biomedical Research Centre.
David has 30 years’ experience in clinical research. In 1999 he joined the Medicines Evaluation Unit Ltd as Director of Operations and was instrumental in turning a grant-funded NHS department into a successful Phase I clinical trials unit and winner of the Queens Award for Enterprise. He is also a Director and co-founder of MEU Solutions Ltd, a CRO offering clinical trials services to Pharma worldwide. Previously he held senior finance roles in the NHS, in the areas of Contracting and Management Accounting. He is a member of the Medicines and Healthcare products Regulatory Agency (MHRA) phase 1 stakeholder committee and also helped develop the NHS clinical trials agreement the mCTA.
Professor Paul O' Brien was appointed CEO of ELAROS 24/7 in April 2012.
Paul has held senior posts in the private sector (Chief Executive), local government (Chief Officer), health (Director in West Essex NHS Trust) and education (Head of Department).
He has previous venture start-up experience having established the Essex Development and Regeneration Agency with a turnover of £8.5 million and funds under management of £15 million - employing 60 planners, economists, surveyors, bid writers and fund managers.
He has extensive experience of public sector transformation having externalised a local government service and more recently the externalisation of a £33 Million NHS Service.
Paul also has broad non-executive board experience gained over a 15 year period and has completed the Institute of Directors Diploma in Company Direction.
Paul's work in business & management education in Russia and Bulgaria, in the 1990s, secured the Queen's Anniversary Prizes for Higher & Further Education.
Paul is a visiting lecturer to the University of Surrey on its MBA & MSc Entrepreneurship programmes.
James has worked for 20+ years around a broad set of technologies and across a wide range of sectors, including; Health, Insurance, Finance, and Travel (The British Library, Jet2 and Confused.com).
James has worked on complex software projects, from building databases, assessing security risks, streamlining backend code to building cloud infrastructure.
Over the past four years James has been working with ELAROS on a range of health apps and on a web-based health commissioning platform.
James is the lead software developer for the Mi-Trial platform.
Henry is the Sales Manager at Mi-Trial, and will be working on the commercialisation of the system. He will also be helping with Regulatory affairs, drawing on his experience as the Regulatory Affairs and IT Manager at ELAROS.
Henry started work with Elaros in March 2021, initially as a part time intern, whilst completing his master’s degree in Healthcare Analytics and Artificial Intelligence at Sheffield Hallam University. Henry’s master’s degree explored the digital health field, including data processing, data protection, ethics, project management and procuring among many other areas. Since completing his Master’s, Henry has continued his work for Elaros, and joined the Mi-trial team.
Henry has a BSc. (Hons) in Biochemistry from the University of Sheffield and he has also completed a PGCE in Secondary Science at the University of Manchester. Henry aims to bring his combination of industry, teaching and academic experience to his role with Mi-Trial.
Stephen has over 20 years' experience in software development and quality assurance. In 2020 he joined the Medicines Evaluation Unit Ltd as a Software Quality Engineer and has been working on their internal software development projects, along with adding his experience to the Mi-Trial application testing process.
Stephen has a degree in Computing in Business from Huddersfield University and has worked in software development and quality assurance across multiple industries from legal (Barristers and Solicitors) to digital marketing, retail, insurance, leisure and hospitality.
Hear what those working with Mi-Trial think of the product and our service